Received Apr 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 2N795 | IM |
wrong route of administration; 68 years patient received a priorix vaccine; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 68-year-old male patient who received MMR (Priorix) (batch number 2N795, expiry date 13-SEP-2026) for prophylaxis. On 17-APR-2025, the patient received Priorix (intramuscular). On 17-APR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: wrong route of administration) and inappropriate age at vaccine administration (Verbatim: 68 years patient received a priorix vaccine). The outcome of the subcutaneous injection formulation administered by other route and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 18-APR-2025 The pharmacist reported a patient received a dose of Priorix via intramuscular injection instead of subcutaneously which led to Subcutaneous injection formulation administered by other route. The 68 year old patient received a dose of Priorix vaccine which led to inappropriate age at vaccine administration.; Sender's Comments: US-GSK-US2025047931:same reporter